3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Carcinoma, Renal Cell
5
Carcinoma, Hepatocellular
3
Triple Negative Breast Neoplasms
2
Lung Neoplasms
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Neoplasms
1
Metastatic Non-Squamous Non-Small Cell Lung Cancer
1
Melanoma
1
Lung Diseases
1
Liposarcoma
1
Head and Neck Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Advanced or Metastatic Solid Malignancies
1
Advanced Solid Tumors
1
Advanced Solid Tumor
1
Advanced Malignancies
1
Advanced Biliary Tract Cancer
1
Adenocarcinoma
1
Interventions
Gemcitabine
4
lenvatinib
3
durvalumab
3
Cisplatin
3
tislelizumab
2
sintilimab
2
pembrolizumab
2
toripalimab
1
titanium silicide
1
theasinensin A
1
surufatinib
1
sitravatinib
1
regorafenib
1
S 1 (combination)
1
Nivolumab
1
Injections
1
Folfox protocol
1
Fluorouracil
1
Cryosurgery
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Advanced Biliary Tract Cancer
×
sitravatinib
×
Clear all
NCT04727996
2024-04-19
BTC-BGB
Seoul National University Hospital
Phase 2
Unknown
43 enrolled